Becton, dickinson and company:1106636 [16-008464]

Ended Awarded Last action

Contract number
HHSN26100011
Awardee
Awarding agency
Obligated
$21,194

Award facts

Opportunity
Contract value 100% obligated
$21,194.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Firm Fixed Price
Place of performance
Bethesda, MD 20892, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00002 $0
Supplemental Agreement for work within scope P00001 · BD HU CD11B/MAC-1 fitc ICRF44 becton, dickinson and company:1106636 [16-008464] -$39
Original award $21,233

About this award

The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on November 19, 2015, with a ceiling value of $21,194.00 for flow cytometric analysis of benign and malignant tumors using BD HU CD11B/MAC-1 FITC ICRF44 reagents.

Place of performance is Bethesda, MD 20892. The order is firm fixed price with an ultimate completion date of September 18, 2017. No set-aside was used.

Quick answers

Who was awarded contract HHSN26100011?

HHSN26100011 was awarded to Becton, Dickinson And Company by National Cancer Institute (National Institutes of Health) on November 19, 2015.

How much is contract HHSN26100011 worth?

The government has obligated $21,194 on HHSN26100011.

Is contract HHSN26100011 an order under another contract?

Yes. HHSN26100011 is a delivery order under HHSN261201400013I, an indefinite delivery contract.

Was contract HHSN26100011 competed?

The extent of competition for HHSN26100011 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award